ImmunityBio, Inc. (NASDAQ: IBRX) has announced a significant financial development, securing $75 million in non-dilutive funding under its existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital. This transaction increases the total committed capital under the agreement to $375 million, providing the company with essential resources to support its global expansion and the advancement of its immunotherapy pipeline. The amended agreement maintains existing terms while slightly increasing the royalty payback rate, ensuring that ImmunityBio can continue to scale its commercial efforts following recent approvals of its product, ANKTIVA, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The funding is expected to bolster the company's operational capabilities and enhance its market presence in the competitive immunotherapy landscape. Additionally, the company reported a simultaneous conversion of $25 million of outstanding promissory notes held by Nant Capital, an entity affiliated with Executive Chairman Dr. Patrick Soon-Shiong, into approximately 4.6 million shares of common stock. This move not only reduces the company's debt but also reflects strong confidence in ImmunityBio's strategic direction and growth potential. The proceeds from the financing will be utilized for general corporate purposes, including transaction expenses related to the amendment and associated documentation. With a robust financial backing and a clear strategy for growth, ImmunityBio is well-positioned to capitalize on emerging opportunities in the immunotherapy sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.